HK1259409A1 - 酪蛋白激酶1δ在乳腺癌中的治療靶向 - Google Patents

酪蛋白激酶1δ在乳腺癌中的治療靶向

Info

Publication number
HK1259409A1
HK1259409A1 HK19101778.5A HK19101778A HK1259409A1 HK 1259409 A1 HK1259409 A1 HK 1259409A1 HK 19101778 A HK19101778 A HK 19101778A HK 1259409 A1 HK1259409 A1 HK 1259409A1
Authority
HK
Hong Kong
Prior art keywords
delta
breast cancer
casein kinase
therapeutic targeting
targeting
Prior art date
Application number
HK19101778.5A
Other languages
English (en)
Inventor
William R Roush
Derek R Duckett
John L Cleveland
Laura H Rosenberg
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HK1259409A1 publication Critical patent/HK1259409A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19101778.5A 2015-10-13 2019-01-31 酪蛋白激酶1δ在乳腺癌中的治療靶向 HK1259409A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562240689P 2015-10-13 2015-10-13
PCT/US2016/055436 WO2017066055A1 (en) 2015-10-13 2016-10-05 THERAPEUTIC TARGETING OF CASEIN KINASE 1δ IN BREAST CANCER

Publications (1)

Publication Number Publication Date
HK1259409A1 true HK1259409A1 (zh) 2019-11-29

Family

ID=58517824

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101778.5A HK1259409A1 (zh) 2015-10-13 2019-01-31 酪蛋白激酶1δ在乳腺癌中的治療靶向

Country Status (8)

Country Link
US (2) US10603322B2 (zh)
EP (1) EP3362452A4 (zh)
JP (1) JP2018538241A (zh)
CN (1) CN108431006A (zh)
AU (1) AU2016338639A1 (zh)
CA (1) CA3001903A1 (zh)
HK (1) HK1259409A1 (zh)
WO (1) WO2017066055A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019217421A1 (en) 2018-05-08 2019-11-14 The Scripps Research Institute Small molecule inhibitors of cdk12/cdk13
WO2020041607A1 (en) * 2018-08-22 2020-02-27 Merck Patent Gmbh Treatment of triple negative breast cancer with targeted tgf-b inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493464B2 (en) * 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
NZ630467A (en) * 2013-01-16 2017-02-24 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US20180311252A1 (en) 2018-11-01
US20200163972A1 (en) 2020-05-28
EP3362452A4 (en) 2019-06-12
US10603322B2 (en) 2020-03-31
CA3001903A1 (en) 2017-04-20
EP3362452A1 (en) 2018-08-22
AU2016338639A1 (en) 2018-05-10
CN108431006A (zh) 2018-08-21
JP2018538241A (ja) 2018-12-27
WO2017066055A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
IL255831A (en) Inhibitors of bruton's tyrosine kinase
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
HK1247129A1 (zh) 治療癌症的聯合療法
HK1251475A1 (zh) 用於癌症治療的聯合療法
HK1246152A1 (zh) 癌症的飲食療法開發
PL3473263T3 (pl) Preparaty łączone do leczenia raka
HK1258319A1 (zh) 癌症療法
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL269357A (en) Combined therapies for the treatment of breast cancer
IL258671A (en) A therapeutic agent for breast cancer
HK1259409A1 (zh) 酪蛋白激酶1δ在乳腺癌中的治療靶向
GB201613167D0 (en) Cancer and b-cell related disease therapy
GB201704909D0 (en) Cancer therapy
GB201711855D0 (en) Cancer therapy
ZA201902951B (en) Nutritional composition for use in therapy of cancer patients
IL268897A (en) A drug to treat a malignant tumor
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment
GB201706046D0 (en) Cancer therapy
GB201700772D0 (en) Cancer therapy
SG11201801083UA (en) Tumor therapeutic agent